Semaglutide denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Imposes Quantity Limits on Semaglutide

Quantity limit (QL) denials mean Humana will cover semaglutide but only up to a defined quantity per dispensing period — typically reflecting the dosing schedule in the FDA-approved prescribing label. A QL denial can occur when a prescription is written for a supply, strength, or titration schedule that exceeds the plan's limit, or when the prescriber's intent (such as initiating with a different quantity to accommodate titration) was not clearly communicated in the PA documentation.

## Why This Denial Is Appealable

Quantity limit exceptions are a recognized part of the appeal process under ACA Section 2719 and ERISA Section 503. If your clinical situation requires a quantity that differs from the default limit — for example, a medically supervised titration schedule or a documented clinical reason — your prescriber can request a quantity limit exception. The external-review window is typically open for approximately four months from the denial date. Urgent situations qualify for expedited review with a decision generally required within 72 hours.

## The Appeal Process

1. Confirm the exact limit applied — the denial letter should state the approved quantity and the requested quantity; verify which is which before appealing. 2. Request a quantity limit exception — Humana must provide a process for this; it is often submitted alongside or as part of the PA process. 3. File the internal appeal if the exception is denied, within the timeframe on your Explanation of Benefits. 4. Escalate to external review if the internal decision is adverse.

## Documentation to Gather

• Prescriber justification letter: a letter explaining why the prescribed quantity is appropriate for this patient's clinical situation, referencing the titration guidance in the FDA-approved prescribing label without inventing dosing numbers.
• FDA-approved prescribing label: reference the dosing section of the label to confirm the prescribed regimen is consistent with approved use.
• Clinical chart notes: document the patient's current status, any dose adjustments made, and the clinical rationale for the prescribed supply.
• Titration schedule documentation: if quantity exceeds a standard fill due to titration, provide the prescriber's documented titration plan.

## Criteria-Mapping Structure

Obtain Humana's quantity limit policy for semaglutide — this may be in the formulary document or the PA criteria. Identify the specific limit and the exception pathway. For each exception criterion, provide the corresponding chart evidence. The most successful quantity limit appeals pair a clear prescriber letter with an explicit reference to the FDA-approved dosing range, demonstrating that the requested quantity is consistent with the label and clinically necessary for this patient.